CA2871314A1 - Process for preparation of 17-substituted steroids - Google Patents
Process for preparation of 17-substituted steroids Download PDFInfo
- Publication number
- CA2871314A1 CA2871314A1 CA2871314A CA2871314A CA2871314A1 CA 2871314 A1 CA2871314 A1 CA 2871314A1 CA 2871314 A CA2871314 A CA 2871314A CA 2871314 A CA2871314 A CA 2871314A CA 2871314 A1 CA2871314 A1 CA 2871314A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- process according
- group
- protecting group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 100
- 230000008569 process Effects 0.000 title claims abstract description 90
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 150000003431 steroids Chemical class 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 159
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 60
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 49
- 239000002904 solvent Substances 0.000 claims description 39
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 33
- 125000006241 alcohol protecting group Chemical group 0.000 claims description 29
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 125000006239 protecting group Chemical group 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 19
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 19
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 19
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 18
- -1 3-substituted pyridinyl Chemical group 0.000 claims description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- 229960004103 abiraterone acetate Drugs 0.000 claims description 14
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims description 14
- 239000002585 base Substances 0.000 claims description 14
- 125000002252 acyl group Chemical group 0.000 claims description 12
- 229910052783 alkali metal Inorganic materials 0.000 claims description 12
- 150000001340 alkali metals Chemical group 0.000 claims description 12
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 8
- 229910052723 transition metal Inorganic materials 0.000 claims description 8
- 150000003624 transition metals Chemical class 0.000 claims description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- 238000007259 addition reaction Methods 0.000 claims description 5
- 230000000397 acetylating effect Effects 0.000 claims description 3
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 239000000543 intermediate Chemical class 0.000 abstract description 4
- 206010060862 Prostate cancer Diseases 0.000 abstract description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 2
- 239000003098 androgen Substances 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 13
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 13
- 239000007787 solid Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 238000006297 dehydration reaction Methods 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 8
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 8
- 238000003379 elimination reaction Methods 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 8
- 239000012265 solid product Substances 0.000 description 8
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 210000003739 neck Anatomy 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 7
- 229940086542 triethylamine Drugs 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000012038 nucleophile Substances 0.000 description 6
- 238000005935 nucleophilic addition reaction Methods 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- 230000003637 steroidlike Effects 0.000 description 6
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000000356 contaminant Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000012039 electrophile Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 238000007344 nucleophilic reaction Methods 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 2
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- 238000006418 Brown reaction Methods 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- UQSQSQZYBQSBJZ-UHFFFAOYSA-M fluorosulfonate Chemical compound [O-]S(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-M 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- ANYSGBYRTLOUPO-UHFFFAOYSA-N lithium tetramethylpiperidide Chemical compound [Li]N1C(C)(C)CCCC1(C)C ANYSGBYRTLOUPO-UHFFFAOYSA-N 0.000 description 2
- JDOZOOBCADNBIJ-UHFFFAOYSA-N lithium;2h-pyridin-2-ide Chemical compound [Li+].C1=CC=N[C-]=C1 JDOZOOBCADNBIJ-UHFFFAOYSA-N 0.000 description 2
- CWJCFOZDFPMHBR-UHFFFAOYSA-N lithium;3h-pyridin-3-ide Chemical compound [Li+].C1=C[C-]=CN=C1 CWJCFOZDFPMHBR-UHFFFAOYSA-N 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- NJXLIOOJACLKHV-UHFFFAOYSA-M [Br-].[Mg+]C1=CC=CN=C1 Chemical compound [Br-].[Mg+]C1=CC=CN=C1 NJXLIOOJACLKHV-UHFFFAOYSA-M 0.000 description 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
- KHHUWSREFUHHDL-UHFFFAOYSA-N [Mg]C1=CC=CC=N1 Chemical compound [Mg]C1=CC=CC=N1 KHHUWSREFUHHDL-UHFFFAOYSA-N 0.000 description 1
- GHASBQYLQLMSOZ-UHFFFAOYSA-N [Zn]C1=CC=CC=N1 Chemical compound [Zn]C1=CC=CC=N1 GHASBQYLQLMSOZ-UHFFFAOYSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 150000007516 brønsted-lowry acids Chemical class 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- BGTOWKSIORTVQH-HOSYLAQJSA-N cyclopentanone Chemical group O=[13C]1CCCC1 BGTOWKSIORTVQH-HOSYLAQJSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- KSBCPTHITUHSPO-UHFFFAOYSA-N methyl 3-hydroxy-4-methoxy-10-nitrophenanthrene-1-carboxylate Chemical compound COC(=O)C1=CC(=C(C=2C3=CC=CC=C3C=C(C1=2)[N+](=O)[O-])OC)O KSBCPTHITUHSPO-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical group [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Abstract
The specification relates to a process for preparation of 17-substituted steroid and intermediates useful therein. Embodiments of 17-substituted steroid have been shown as useful for treatment of androgen-dependent disorders, especially prostatic cancer, and also oestrogen-dependent5 disorders such as breast cancer.
Description
This application claims priority to and the benefit of United States Provisional Patent Application Serial Number 61/637,048 filed April 23, 2012, and Provisional Patent Application No. 61/642,253 filed May 3, 2012, the subject matter of which is incorporated herein by reference.
FIELD
[0001]
The specification relates to a process for preparation of 17-substitued steroids, and intermediates useful therein.
BACKGROUND
FIELD
[0001]
The specification relates to a process for preparation of 17-substitued steroids, and intermediates useful therein.
BACKGROUND
[0002]
Abiraterone acetate has been disclosed as an androgen biosynthesis inhibitor, and was approved and launched in the U.S. in 2011 in combination with prednisone for the oral treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel (US
5,604,213; FDA News Release 28 Apr, 2011, (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253055.ht in, incorporated herein by reference)). Abiraterone acetate has been commercially marketed as ZytigaTM. The structure of abiraterone acetate along with numbering of the carbon atoms is shown below.
N
9 11111110, 16 Abi raterone at_etate [0003] The published routes (US Patent Nos 5,604,213 and 5,618,807, incorporated herein by reference) toward abiraterone acetate start with dehydroepiandrosterone (DHEA) and involve manipulation of the cyclopentanone moiety to install the pyridyl group. The preferred method appears to be a Suzuki-type cross coupling reaction involving a pyridylborane and an appropriately substituted steroid, as shown below.
N
O.
? S.
y.
]=== ER2 1.*
)?
=
X. 01T or I
Abiraterone acetate has been disclosed as an androgen biosynthesis inhibitor, and was approved and launched in the U.S. in 2011 in combination with prednisone for the oral treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel (US
5,604,213; FDA News Release 28 Apr, 2011, (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253055.ht in, incorporated herein by reference)). Abiraterone acetate has been commercially marketed as ZytigaTM. The structure of abiraterone acetate along with numbering of the carbon atoms is shown below.
N
9 11111110, 16 Abi raterone at_etate [0003] The published routes (US Patent Nos 5,604,213 and 5,618,807, incorporated herein by reference) toward abiraterone acetate start with dehydroepiandrosterone (DHEA) and involve manipulation of the cyclopentanone moiety to install the pyridyl group. The preferred method appears to be a Suzuki-type cross coupling reaction involving a pyridylborane and an appropriately substituted steroid, as shown below.
N
O.
? S.
y.
]=== ER2 1.*
)?
=
X. 01T or I
[0004] The known synthetic route can have certain drawbacks, such as the use of expensive reagents (triflate). In addition, the synthetic route can lead to an elimination side product, forming a double bond between the C3 and C4 position.
Further, the coupling reaction with pyridylborane utilizes a palladium (Pd) catalyst and boranes at the final synthetic step, which need to be removed from the active pharmaceutical ingredient (API), and can require column chromatographic purification. Moreover, US Patent No. 5,618,807 discloses in Example 20 that the coupling reaction leads to an impurity (16,17'-bis(steroidal) contaminant) in significant amounts (6.8% w/w), which crystallization was unsuccessful in removing. Further to the above, the compounds prepared in the process for preparation of abiraterone acetate can require column chromatography, which usually is undesirable, especially for manufacturing at industrial scale.
[0005] Hence, there is a need in the art for a process for preparation of abiraterone acetate that can avoid the use of expensive reagents, the elimination reaction, the formation of additional impurities or formation of the bis(steroidal) contaminant. In addition, there is a need in the art for a process for preparation of abiraterone acetate that can avoid or reduce the use of column chromatography.
Further, there is a need in the art for a process for preparation of abiraterone acetate, where any one of the intermediates or final product prepared is in high purity and can be purified by crystallization. Moreover, there is a need in the art for an alternate route to synthesis of 17-substituted steroids, which is suitable for large scale production.
SUMMARY OF INVENTION
Further, the coupling reaction with pyridylborane utilizes a palladium (Pd) catalyst and boranes at the final synthetic step, which need to be removed from the active pharmaceutical ingredient (API), and can require column chromatographic purification. Moreover, US Patent No. 5,618,807 discloses in Example 20 that the coupling reaction leads to an impurity (16,17'-bis(steroidal) contaminant) in significant amounts (6.8% w/w), which crystallization was unsuccessful in removing. Further to the above, the compounds prepared in the process for preparation of abiraterone acetate can require column chromatography, which usually is undesirable, especially for manufacturing at industrial scale.
[0005] Hence, there is a need in the art for a process for preparation of abiraterone acetate that can avoid the use of expensive reagents, the elimination reaction, the formation of additional impurities or formation of the bis(steroidal) contaminant. In addition, there is a need in the art for a process for preparation of abiraterone acetate that can avoid or reduce the use of column chromatography.
Further, there is a need in the art for a process for preparation of abiraterone acetate, where any one of the intermediates or final product prepared is in high purity and can be purified by crystallization. Moreover, there is a need in the art for an alternate route to synthesis of 17-substituted steroids, which is suitable for large scale production.
SUMMARY OF INVENTION
[0006] In one aspect, the specification discloses a process for preparation of the compound of formula 4, the process containing the steps of:
o A r ow O. elle 510 _.
RO RO
A r Ar O.
ell. ___________________________________________ "Pi' 110411".
RO
- nucleophillic addition reaction of the compound of formula 1 with a compound of formula Ar-M to form the compound of formula 2;
- dehydrating the compound of formula 2 to form the compound of formula 3 or 4;
- optionally, deprotecting the compound of formula 3; and - optionally, acylating the compound of formula 3 to form the compound of formula 4, wherein R is H or an alcohol protecting group;
R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group;
M is alkali metal, alkali earth metal or a transition metal of group 11 or 12;
Ar is an aryl or heteroaryl group and Ac is an acyl group.
o A r ow O. elle 510 _.
RO RO
A r Ar O.
ell. ___________________________________________ "Pi' 110411".
RO
- nucleophillic addition reaction of the compound of formula 1 with a compound of formula Ar-M to form the compound of formula 2;
- dehydrating the compound of formula 2 to form the compound of formula 3 or 4;
- optionally, deprotecting the compound of formula 3; and - optionally, acylating the compound of formula 3 to form the compound of formula 4, wherein R is H or an alcohol protecting group;
R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group;
M is alkali metal, alkali earth metal or a transition metal of group 11 or 12;
Ar is an aryl or heteroaryl group and Ac is an acyl group.
[0007] In another aspect, the specification relates to the compound of formula 2, Ar Oe RO
wherein 10 Ar is an aryl or heteroaryl group;
R is H or an alcohol protecting group; and R' is H, an alcohol protecting group or R' together with the oxygen to which it is attached forms a leaving group.
wherein 10 Ar is an aryl or heteroaryl group;
R is H or an alcohol protecting group; and R' is H, an alcohol protecting group or R' together with the oxygen to which it is attached forms a leaving group.
[0008] In a further aspect, the specification relates to the compound of 15 formula 3, RO
wherein Ar is an aryl or heteroaryl group; and R is a silyl-based protecting group.
5 [0009] In a still further aspect, the specification relates to abiraterone acetate having a purity of ?950/0, 960/(:), 970/(:), -98 /0, -99 A:), 99.5% or ?99.90!o, as determined by HPLC.
[0010] In still another aspect, the specification relates to abiraterone acetate substantially free of the bis(steroidal) contaminant as determined by HPLC
analysis.
10 [0011] In still another aspect, the specification relates to the compound of formula 3 having a purity of 95%, 96%, 97%, 98%, 99 /o, 99.5% or ?99.9%, as determined by HPLC.
[0012] In another further aspect, the specification relates to the compound of formula 2 having a purity of ?95%, ?96%, ?97%, ?98%, ?99%, ?99.5% or 15 99.9%, as determined by HPLC.
[0013] In another still further aspect, the specification relates to a process for purification of the compound of formula 3 or 4, as disclosed herein, by recrystallization of the compound of formula 3 or 4.
DESCRIPTION
[0014] A process for preparation of the compound of formula 4, the process containing the steps of:
o Pir ow O. 41111.
RO
RU
Pr Ar es Oil Sr _Jo,.
RO
- nucleophillic addition reaction of the compound of formula 1 with a compound of formula Ar-M to form the compound of formula 2;
- dehydrating the compound of formula 2 to form the compound of formula 3 or 4;
- optionally, deprotecting the compound of formula 3; and - optionally, acylating the compound of formula 3 to form the compound of formula 4, wherein R is H or an alcohol protecting group;
R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group;
M is alkali metal, alkali earth metal or a transition metal of group 11 or 12;
Ar is an aryl or heteroaryl group and Ac is an acyl group.
[0015] The term "alcohol protecting group" as used herein is not particularly limited, and should be known to a skilled worker or can be determined. In one embodiment, for example and without limitation, the protecting group forms an ester, ether or is a silyl-based protecting group. In a further, embodiment for example and without limitation, the ester formed is acetyl (Ac), benzoyl (Bz) or pivaloyl (Piv). In another embodiment, for example and without limitation, the ether protecting group formed is benzyl (Bn), 8-methoxyethoxymethyl ether (MEM), trityl (Tr), dimethoxy trityl (DMT), methoxymethyl ether (MOM), or the like. In a still further embodiment, for example and without limitation, the silyl-based protecting group formed is tert-butyldimethylsilyl (TBDMS or TBS), tri-iso-propylsilyloxymethyl (TOM), or triisopropylsilyl (TIPS).
[0016] A "leaving group" as disclosed herein is a molecular fragment or stable species that can be detached from a molecule in a bond-breaking step. The process can also involve, for example and without limitation, a bond-breaking step between the leaving group and molecule, along with formation of a double bond in the molecule. The leaving group, in accordance with the specification, is not particularly limited and should be known to a person of skill in the art or can be determined. The ability of a leaving group to depart is correlated with the pK, of the conjugate acid, with lower pKa being associated with better leaving group ability. Examples of a leaving group include, without limitation, an acyl ester or a sulfonate. Examples of sulfonates can include, without limitation, nonaflate, triflate, fluorosulfonate, tosylate, mesylate or besylate. In one embodiment, for example and without limitation, the leaving group is mesylate or tosylate.
[0017] The term "alkali metal" as used herein is not particularly limited, and should be known to a person of skill in the art. Alkali metals contain the group 1 elements of the periodic table, excluding hydrogen, and include lithium (Li), sodium (Na), potassium (K), rubidium (Rb) and caesium (Cs). In one embodiment, for example and without limitation, the alkali metals used in accordance with the specification include lithium (Li), sodium (Na) or potassium (K). In a further embodiment, for example and without limitation, the alkali metal used in accordance with the specification includes lithium (Li).
[0018] The term "alkali earth metal" as used herein is not particularly limited, and should be known to a person of skill in the art. Alkali earth metals contain group 2 elements of the periodic table, and can include, for example, beryllium (Be), magnesium (Mg), calcium (Ca), Strontium (Sr), Barium (Ba). In one embodiment, for example and without limitation, the alkali earth metal used in accordance with the specification is magnesium (Mg).
[0019] The term "transition metals of group 11 or 12" should be understood by a skilled worker, and includes transition metals of group 11 or 12 of the periodic table. The transition metals of group 11 can include copper (Cu) and silver (Ag), while the transition metals of group 12 can include zinc (Zn), cadmium (Cd) and mercury (Hg).
[0020] The term "aryl" as used herein is not particularly limited, and should be known to a person of skill in the art. The term "aryl" as used herein refers to any functional group or substituent derived from an aromatic carbocyclic ring.
In one embodiment, for example and without limitation, the aryl group is a C6-14 aryl.
The term "aryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
Examples of aryl include, for example and without limitation, phenyl, naphthyl, anthracenyl, and phenanthrenyl.
[0021] The term "heteroaryl" as used herein is not particularly limited, and should be known to a person of skill in the art. The term "heteroaryl" as used herein refers to any functional group or substituent derived from an aromatic ring where one or more of the atoms in the aromatic ring is of an element other than carbon. In another embodiment, for example and without limitation, heteroaryl includes 5-, 6-, and 7-membered substituted or unsubstituted single-ring aromatic groups that can have one or more heteroatonns as part of the ring system.
Examples of heteroaryls include, for example and without limitation, pyridinyl, pyrazinyl, imidazolyl, pyrazolyl, oxazolyl, or thiophenyl. In a further embodiment in accordance with the specification, the heteroaryl group is a pyridinyl.
[0022] The term "acyl group" as used herein is not particularly limited and should be known to a skilled worker. In one embodiment, for example and without limitation, the acyl group refers to the general formula "RC(=0)-" , where R
is a hydrocarbon; and can also include the acyl protecting groups noted herein. In a further embodiment in accordance with the specification, the acyl group is, for example and without limitation, acetyl (Ac), benzoyl (Bz) or pivaloyl (Piv).
In a still further embodiment in accordance with the specification, the acyl group is, for example and without limitation, acetyl (Ac).
[0023] The term "hydrocarbon", as used herein, refers to a group that contains hydrogen and carbon, linked generally via a carbon backbone, but can optionally include heteroatoms. Hydrocarbyl groups include, but are not limited to alkyl, aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof. Thus, groups like methyl, ethoxyethyl, 2-pyridyl, and trifluoromethyl are considered to be hydrocarbyl for the purposes of this specification.
[0024] The term "heteroatom", is not particularly limited and should be understood by a skilled worker. As used herein, the term means an atom of any element other than carbon or hydrogen. In one embodiment, for the example and without limitation, heteroatoms include nitrogen, oxygen, and sulfur.
[0025] The term "alkyl" as used herein is not particularly limited and should be known to a person of skill in the art; and refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl, etc. In one embodiment, for example and without limitation, the alkyl group is a C1-6 alkyl.
[0026] The term "C1_6 alkyl" in accordance with the specification is not particularly limited and should be known to a person of skill in the art. The alkyl may be, for example, and without limitation, any straight or branched alkyl, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, i-pentyl, sec-pentyl, t-pentyl, n-hexyl, i-hexyl, 1,2-dimethylpropyl, methylbutyl, 1,2-dimethylbutyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-ethylbutyl, 1,3-dimethylbutyl, 2-methylpentyl or 3-methylpentyl.
wherein Ar is an aryl or heteroaryl group; and R is a silyl-based protecting group.
5 [0009] In a still further aspect, the specification relates to abiraterone acetate having a purity of ?950/0, 960/(:), 970/(:), -98 /0, -99 A:), 99.5% or ?99.90!o, as determined by HPLC.
[0010] In still another aspect, the specification relates to abiraterone acetate substantially free of the bis(steroidal) contaminant as determined by HPLC
analysis.
10 [0011] In still another aspect, the specification relates to the compound of formula 3 having a purity of 95%, 96%, 97%, 98%, 99 /o, 99.5% or ?99.9%, as determined by HPLC.
[0012] In another further aspect, the specification relates to the compound of formula 2 having a purity of ?95%, ?96%, ?97%, ?98%, ?99%, ?99.5% or 15 99.9%, as determined by HPLC.
[0013] In another still further aspect, the specification relates to a process for purification of the compound of formula 3 or 4, as disclosed herein, by recrystallization of the compound of formula 3 or 4.
DESCRIPTION
[0014] A process for preparation of the compound of formula 4, the process containing the steps of:
o Pir ow O. 41111.
RO
RU
Pr Ar es Oil Sr _Jo,.
RO
- nucleophillic addition reaction of the compound of formula 1 with a compound of formula Ar-M to form the compound of formula 2;
- dehydrating the compound of formula 2 to form the compound of formula 3 or 4;
- optionally, deprotecting the compound of formula 3; and - optionally, acylating the compound of formula 3 to form the compound of formula 4, wherein R is H or an alcohol protecting group;
R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group;
M is alkali metal, alkali earth metal or a transition metal of group 11 or 12;
Ar is an aryl or heteroaryl group and Ac is an acyl group.
[0015] The term "alcohol protecting group" as used herein is not particularly limited, and should be known to a skilled worker or can be determined. In one embodiment, for example and without limitation, the protecting group forms an ester, ether or is a silyl-based protecting group. In a further, embodiment for example and without limitation, the ester formed is acetyl (Ac), benzoyl (Bz) or pivaloyl (Piv). In another embodiment, for example and without limitation, the ether protecting group formed is benzyl (Bn), 8-methoxyethoxymethyl ether (MEM), trityl (Tr), dimethoxy trityl (DMT), methoxymethyl ether (MOM), or the like. In a still further embodiment, for example and without limitation, the silyl-based protecting group formed is tert-butyldimethylsilyl (TBDMS or TBS), tri-iso-propylsilyloxymethyl (TOM), or triisopropylsilyl (TIPS).
[0016] A "leaving group" as disclosed herein is a molecular fragment or stable species that can be detached from a molecule in a bond-breaking step. The process can also involve, for example and without limitation, a bond-breaking step between the leaving group and molecule, along with formation of a double bond in the molecule. The leaving group, in accordance with the specification, is not particularly limited and should be known to a person of skill in the art or can be determined. The ability of a leaving group to depart is correlated with the pK, of the conjugate acid, with lower pKa being associated with better leaving group ability. Examples of a leaving group include, without limitation, an acyl ester or a sulfonate. Examples of sulfonates can include, without limitation, nonaflate, triflate, fluorosulfonate, tosylate, mesylate or besylate. In one embodiment, for example and without limitation, the leaving group is mesylate or tosylate.
[0017] The term "alkali metal" as used herein is not particularly limited, and should be known to a person of skill in the art. Alkali metals contain the group 1 elements of the periodic table, excluding hydrogen, and include lithium (Li), sodium (Na), potassium (K), rubidium (Rb) and caesium (Cs). In one embodiment, for example and without limitation, the alkali metals used in accordance with the specification include lithium (Li), sodium (Na) or potassium (K). In a further embodiment, for example and without limitation, the alkali metal used in accordance with the specification includes lithium (Li).
[0018] The term "alkali earth metal" as used herein is not particularly limited, and should be known to a person of skill in the art. Alkali earth metals contain group 2 elements of the periodic table, and can include, for example, beryllium (Be), magnesium (Mg), calcium (Ca), Strontium (Sr), Barium (Ba). In one embodiment, for example and without limitation, the alkali earth metal used in accordance with the specification is magnesium (Mg).
[0019] The term "transition metals of group 11 or 12" should be understood by a skilled worker, and includes transition metals of group 11 or 12 of the periodic table. The transition metals of group 11 can include copper (Cu) and silver (Ag), while the transition metals of group 12 can include zinc (Zn), cadmium (Cd) and mercury (Hg).
[0020] The term "aryl" as used herein is not particularly limited, and should be known to a person of skill in the art. The term "aryl" as used herein refers to any functional group or substituent derived from an aromatic carbocyclic ring.
In one embodiment, for example and without limitation, the aryl group is a C6-14 aryl.
The term "aryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
Examples of aryl include, for example and without limitation, phenyl, naphthyl, anthracenyl, and phenanthrenyl.
[0021] The term "heteroaryl" as used herein is not particularly limited, and should be known to a person of skill in the art. The term "heteroaryl" as used herein refers to any functional group or substituent derived from an aromatic ring where one or more of the atoms in the aromatic ring is of an element other than carbon. In another embodiment, for example and without limitation, heteroaryl includes 5-, 6-, and 7-membered substituted or unsubstituted single-ring aromatic groups that can have one or more heteroatonns as part of the ring system.
Examples of heteroaryls include, for example and without limitation, pyridinyl, pyrazinyl, imidazolyl, pyrazolyl, oxazolyl, or thiophenyl. In a further embodiment in accordance with the specification, the heteroaryl group is a pyridinyl.
[0022] The term "acyl group" as used herein is not particularly limited and should be known to a skilled worker. In one embodiment, for example and without limitation, the acyl group refers to the general formula "RC(=0)-" , where R
is a hydrocarbon; and can also include the acyl protecting groups noted herein. In a further embodiment in accordance with the specification, the acyl group is, for example and without limitation, acetyl (Ac), benzoyl (Bz) or pivaloyl (Piv).
In a still further embodiment in accordance with the specification, the acyl group is, for example and without limitation, acetyl (Ac).
[0023] The term "hydrocarbon", as used herein, refers to a group that contains hydrogen and carbon, linked generally via a carbon backbone, but can optionally include heteroatoms. Hydrocarbyl groups include, but are not limited to alkyl, aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof. Thus, groups like methyl, ethoxyethyl, 2-pyridyl, and trifluoromethyl are considered to be hydrocarbyl for the purposes of this specification.
[0024] The term "heteroatom", is not particularly limited and should be understood by a skilled worker. As used herein, the term means an atom of any element other than carbon or hydrogen. In one embodiment, for the example and without limitation, heteroatoms include nitrogen, oxygen, and sulfur.
[0025] The term "alkyl" as used herein is not particularly limited and should be known to a person of skill in the art; and refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl, etc. In one embodiment, for example and without limitation, the alkyl group is a C1-6 alkyl.
[0026] The term "C1_6 alkyl" in accordance with the specification is not particularly limited and should be known to a person of skill in the art. The alkyl may be, for example, and without limitation, any straight or branched alkyl, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, i-pentyl, sec-pentyl, t-pentyl, n-hexyl, i-hexyl, 1,2-dimethylpropyl, methylbutyl, 1,2-dimethylbutyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-ethylbutyl, 1,3-dimethylbutyl, 2-methylpentyl or 3-methylpentyl.
[0027] The term "nucleophilic addition reaction" as used herein is not particularly limited and should be known to a skilled worker. Nucleophilic addition reaction can be considered an addition reaction where in a chemical compound a 7c-bond is removed by creation of two new a-bonds by the addition of a nucleophile.
The term "nucleophile" as used herein is not particularly limited and should be known to a skilled worker. Nucleophile can be considered as a species that donate an electron-pair to an electrophile to form a chemical bond in a reaction. All molecules or ions with a free pair of electrons or at least one pi bond can act as nucleophiles. The term "electrophile" is also not particularly limited and should be known to a skilled worker. An electrophile (literally electron-lover) can be considered as a reagent attracted to electrons that participates in a chemical reaction by accepting an electron pair in order to bond to a nucleophile.
[0028] In the process as disclosed herein, "Ar" in the compound Ar-M
can act as the nucleophile, while carbonyl carbon can act as the electrophile. Without being particularly limited, various embodiments of the compound Ar-NI can be used so long as the nucleophilic addition of Ar to the carbonyl carbon can take place.
In one embodiment, the term Ar-M can include, for example and without limitation, 3-pyridinyl lithium, phenyl magnesium bromide or 3-pyridinyl magnesium bromide.
In a further embodiment, for example and without limitation, the term Ar-M can include 3-pyridinyl lithium.
[0029] The term "dehydrating a compound", as used herein is not particularly limited and should be known to a skilled worker. A dehydration reaction can be considered as an elimination reaction that involves the loss of water, or analogue, from the reacting molecule, and which can lead to formation of an additional bond.
The method of performing the dehydration reaction is not particularly limited.
In one embodiment, for example and without limitation, the dehydration reaction is carried out using an acid or a base.
The term "nucleophile" as used herein is not particularly limited and should be known to a skilled worker. Nucleophile can be considered as a species that donate an electron-pair to an electrophile to form a chemical bond in a reaction. All molecules or ions with a free pair of electrons or at least one pi bond can act as nucleophiles. The term "electrophile" is also not particularly limited and should be known to a skilled worker. An electrophile (literally electron-lover) can be considered as a reagent attracted to electrons that participates in a chemical reaction by accepting an electron pair in order to bond to a nucleophile.
[0028] In the process as disclosed herein, "Ar" in the compound Ar-M
can act as the nucleophile, while carbonyl carbon can act as the electrophile. Without being particularly limited, various embodiments of the compound Ar-NI can be used so long as the nucleophilic addition of Ar to the carbonyl carbon can take place.
In one embodiment, the term Ar-M can include, for example and without limitation, 3-pyridinyl lithium, phenyl magnesium bromide or 3-pyridinyl magnesium bromide.
In a further embodiment, for example and without limitation, the term Ar-M can include 3-pyridinyl lithium.
[0029] The term "dehydrating a compound", as used herein is not particularly limited and should be known to a skilled worker. A dehydration reaction can be considered as an elimination reaction that involves the loss of water, or analogue, from the reacting molecule, and which can lead to formation of an additional bond.
The method of performing the dehydration reaction is not particularly limited.
In one embodiment, for example and without limitation, the dehydration reaction is carried out using an acid or a base.
[0030] The term "acid" as used herein is not particularly limited and should be known to a skilled worker. An acid can be considered as a substance that can act as a proton donor (Bronsted-Lowry acid) or an electron pair acceptor (Lewis acid).
In one embodiment, the acid used in the process disclosed herein is, for example and without limitation, hydrochloric acid (HCI), hydrobromic acid (H Br), acetic acid (CH3CO2H), sulfuric acid (H2SO4) or p-toluenesulfonic acid (p-TSA).
[0031] The term "base" as used herein is not particularly limited and should be known to a skilled worker. A base can be considered as a substance that can accept hydrogen ions (protons) or donate an electron pair. In one embodiment, the base used in the process disclosed herein is, for example and without limitation, triethylamine (TEA), N,N-diisopropylethylamine, (DIPEA), 1,8-diazabicycloundec-ene (DBU), sodium tert-butoxide (t-BuONa), potassium tert-butoxide (t-BuOK), lithium diisopropylamide (LDA), sodium bis(trimethylsilyl)amide (NaHMDS), potassium bis(trimethylsilyl)amide (KHMDS) or lithium tetramethylpiperidide (LiTMP). In a further embodiment, for example and without limitation, the base used in the process disclosed herein is triethylamine (TEA).
[0032] The step of deprotecting the compound of formula 3 as disclosed herein can be optional depending upon the substituents present. Further, the step of deprotection is not particularly limited and should be known to a skilled worker or can be determined. The method of carrying out the deprotection step can depend upon the substituent. In one embodiment, for example and without limitation, deprotection is carried out using an acid. The acid used for deprotection is not particularly limited and should be known to a skilled worker or can be determined. Examples of an acid include acids as are described herein.
[0033] In another embodiment, the step of deprotection is carried out, for example and without limitation, using a fluoride source. The fluoride source is not particularly limited and should be known to a skilled worker or can be determined.
In one embodiment, for example and without limitation, the fluoride source is sodium fluoride (NaF), tetra-butyl ammonium fluoride or pyridine hydrofluoride (HF-Py). The step of deprotection using a fluoride source can be carried out, for example, when the protecting group is a silyl-based protecting group, as described herein.
[0034] The step of acylating the compound of formula 3 as disclosed herein can be optional depending upon the substituent present. As used herein, acylation can be considered as the process of adding an acyl group to a compound.
Further, the step of acylation is not particularly limited and should be known to a skilled worker or can be determined. In one embodiment, for example and without limitation, the step of acylation involves acetylating the compound of formula 3, where R is H. The process of acetylation is not particularly limited and should be known to a skilled worker or can be determined. In one embodiment, for example and without limitation, the step of acetylation is carried out using acetic anhydride (Ac20) or acetyl chloride (AcCI), in the presence of base. The base used is not particularly limited and can include one of the bases as noted herein.
[0035] Referring to Scheme 1 shown below, an embodiment of the process as disclosed herein is further described.
In one embodiment, the acid used in the process disclosed herein is, for example and without limitation, hydrochloric acid (HCI), hydrobromic acid (H Br), acetic acid (CH3CO2H), sulfuric acid (H2SO4) or p-toluenesulfonic acid (p-TSA).
[0031] The term "base" as used herein is not particularly limited and should be known to a skilled worker. A base can be considered as a substance that can accept hydrogen ions (protons) or donate an electron pair. In one embodiment, the base used in the process disclosed herein is, for example and without limitation, triethylamine (TEA), N,N-diisopropylethylamine, (DIPEA), 1,8-diazabicycloundec-ene (DBU), sodium tert-butoxide (t-BuONa), potassium tert-butoxide (t-BuOK), lithium diisopropylamide (LDA), sodium bis(trimethylsilyl)amide (NaHMDS), potassium bis(trimethylsilyl)amide (KHMDS) or lithium tetramethylpiperidide (LiTMP). In a further embodiment, for example and without limitation, the base used in the process disclosed herein is triethylamine (TEA).
[0032] The step of deprotecting the compound of formula 3 as disclosed herein can be optional depending upon the substituents present. Further, the step of deprotection is not particularly limited and should be known to a skilled worker or can be determined. The method of carrying out the deprotection step can depend upon the substituent. In one embodiment, for example and without limitation, deprotection is carried out using an acid. The acid used for deprotection is not particularly limited and should be known to a skilled worker or can be determined. Examples of an acid include acids as are described herein.
[0033] In another embodiment, the step of deprotection is carried out, for example and without limitation, using a fluoride source. The fluoride source is not particularly limited and should be known to a skilled worker or can be determined.
In one embodiment, for example and without limitation, the fluoride source is sodium fluoride (NaF), tetra-butyl ammonium fluoride or pyridine hydrofluoride (HF-Py). The step of deprotection using a fluoride source can be carried out, for example, when the protecting group is a silyl-based protecting group, as described herein.
[0034] The step of acylating the compound of formula 3 as disclosed herein can be optional depending upon the substituent present. As used herein, acylation can be considered as the process of adding an acyl group to a compound.
Further, the step of acylation is not particularly limited and should be known to a skilled worker or can be determined. In one embodiment, for example and without limitation, the step of acylation involves acetylating the compound of formula 3, where R is H. The process of acetylation is not particularly limited and should be known to a skilled worker or can be determined. In one embodiment, for example and without limitation, the step of acetylation is carried out using acetic anhydride (Ac20) or acetyl chloride (AcCI), in the presence of base. The base used is not particularly limited and can include one of the bases as noted herein.
[0035] Referring to Scheme 1 shown below, an embodiment of the process as disclosed herein is further described.
Step2 N
o Stepl / 'N
Oe TBSCI
_,,..
Et3N
le*
_J.-Br Oe OH
Ole DMAP
HO
DMF O. n BuLi Ole TBSO
la lb 2b 1 MsCI Step3 Et3N
/ 'N SteP4 DCM / \
N
/ \ N Step6 HO
-..(-Di axed e 0140 Pyridi ne OS
O
HO TBSO
Ac0 4 3c 3b Scheme 1 [0036]
Step 1 involves protecting the hydroxyl group of compound of formula la to form the compound of formula lb. The protecting group used is a silyl-based protecting group, and is tert-butyldimethylsilyl (TBS), although other protecting groups, including other silyl-based protecting groups can be used. The use of the silyl-based protecting group, such as the tert-butyldimethylsilyl (TBS), can avoid generation of or reduce the amount of the impurity having a double bond at the C3-C4 position. As noted above, the impurity having a double bond between the C3-C4 position can be formed in an elimination reaction, for example in the presence of a base, where, for example, an acetate (leaving group) at the C3 position is removed and a double bond formed. Upon completion of the reaction, the reaction mixture can be quenched using water, which can allow precipitation of the solid product that can be separated by filtration.
o Stepl / 'N
Oe TBSCI
_,,..
Et3N
le*
_J.-Br Oe OH
Ole DMAP
HO
DMF O. n BuLi Ole TBSO
la lb 2b 1 MsCI Step3 Et3N
/ 'N SteP4 DCM / \
N
/ \ N Step6 HO
-..(-Di axed e 0140 Pyridi ne OS
O
HO TBSO
Ac0 4 3c 3b Scheme 1 [0036]
Step 1 involves protecting the hydroxyl group of compound of formula la to form the compound of formula lb. The protecting group used is a silyl-based protecting group, and is tert-butyldimethylsilyl (TBS), although other protecting groups, including other silyl-based protecting groups can be used. The use of the silyl-based protecting group, such as the tert-butyldimethylsilyl (TBS), can avoid generation of or reduce the amount of the impurity having a double bond at the C3-C4 position. As noted above, the impurity having a double bond between the C3-C4 position can be formed in an elimination reaction, for example in the presence of a base, where, for example, an acetate (leaving group) at the C3 position is removed and a double bond formed. Upon completion of the reaction, the reaction mixture can be quenched using water, which can allow precipitation of the solid product that can be separated by filtration.
[0037] Nucleophilic addition reaction of the compound of formula lb with pyridinyl lithium in step 2, leads to formation of the compound of formula 2b.
Other pyridinyl-metal complexes can be used for nucleophilic addition. These include, for example and without limitation, pyridinyl-magnesium, pyridinyl-cuprate or pyridinyl-zinc reagent. The use of pyridinyl lithium can help avoid use of more toxic metals and can provide cleaner and safer reaction conditions.
[0038] The reaction conditions, such as, for example and without limitation, solvent, temperature and ratio of reagents, for the nucleophilic reaction can vary.
The solvent used in the nucleophilic reaction in Step 2 of Scheme 1, can include, for example, toluene, tetrahydrofuran (THF), dimethyl ether (DME) or diethyl ether. In one embodiment, the solvent used in Step 2, as shown in Scheme 1, is toluene.
[0039] The temperature for carrying out the nucleophilic coupling reaction can also vary. Temperatures for the nucleophilic coupling reaction can range from low temperatures, such as, for example and without limitation, -80 C to higher temperatures, such as, for example and without limitation, 50 C. In one embodiment, the temperature for carrying out the nucleophilic addition reaction, as shown in Step 2 of Scheme 1, is from -80 C to 25 C, and values in between. In another embodiment, the temperature can range from -80 C to 0 C, -75 C to -10 C, -70 C to -20 C, -70 C to -40 C or -70 C to -60 C.
[0040] Upon completion, the reaction can be quenched using an aqueous solution, which can include, for example and without limitation, brine.
Extraction and evaporation of the organic layer can provide crude compound 2b. Crude compound 2b can be triturated with an organic solvent to provide compound 2b that can be used in subsequent process steps without further purification. The solvent used for trituration can vary. In one embodiment, in the process step 2 as shown in Scheme 1 above, trituration was performed using acetonitrile.
Other pyridinyl-metal complexes can be used for nucleophilic addition. These include, for example and without limitation, pyridinyl-magnesium, pyridinyl-cuprate or pyridinyl-zinc reagent. The use of pyridinyl lithium can help avoid use of more toxic metals and can provide cleaner and safer reaction conditions.
[0038] The reaction conditions, such as, for example and without limitation, solvent, temperature and ratio of reagents, for the nucleophilic reaction can vary.
The solvent used in the nucleophilic reaction in Step 2 of Scheme 1, can include, for example, toluene, tetrahydrofuran (THF), dimethyl ether (DME) or diethyl ether. In one embodiment, the solvent used in Step 2, as shown in Scheme 1, is toluene.
[0039] The temperature for carrying out the nucleophilic coupling reaction can also vary. Temperatures for the nucleophilic coupling reaction can range from low temperatures, such as, for example and without limitation, -80 C to higher temperatures, such as, for example and without limitation, 50 C. In one embodiment, the temperature for carrying out the nucleophilic addition reaction, as shown in Step 2 of Scheme 1, is from -80 C to 25 C, and values in between. In another embodiment, the temperature can range from -80 C to 0 C, -75 C to -10 C, -70 C to -20 C, -70 C to -40 C or -70 C to -60 C.
[0040] Upon completion, the reaction can be quenched using an aqueous solution, which can include, for example and without limitation, brine.
Extraction and evaporation of the organic layer can provide crude compound 2b. Crude compound 2b can be triturated with an organic solvent to provide compound 2b that can be used in subsequent process steps without further purification. The solvent used for trituration can vary. In one embodiment, in the process step 2 as shown in Scheme 1 above, trituration was performed using acetonitrile.
[0041] The hydroxyl group formed in step 2 can be converted into a leaving group in step 3, by reaction with mesyl chloride to form a mesylate, which can then undergo a dehydration reaction in the presence of a base to form compound 3b.
The leaving group formed can vary and different leaving groups can be used for the elimination reaction to form the double bond. In one embodiment, the hydroxyl group is converted into a sulfonate-based leaving group, which can include, for example and without limitation, nonaflate, triflate, fluorosulfonate, tosylate, mesylate or besylate, as noted above. In another embodiment, as shown in Scheme 2 below, dehydration of the alcohol is performed in the presence of an acid, where H20 forms the leaving group. The sulfonate-based leaving groups can form good leaving groups and can help in improving the overall elimination reaction to form the double bond. In a further embodiment, the sulfonate-based leaving group is a mesylate.
[0042] The reaction conditions, such as, for example and without limitation, solvent, temperature and ratio of reagents, for the dehydration reaction can vary.
The solvent used in the nucleophilic reaction in Step 3 of Scheme 1, can include, for example, dichloromethane (DCM), toluene, tetrahydrofuran (THF), dimethyl ether (DME) or diethyl ether. In one embodiment, the solvent used in Step 3, as shown in Scheme 1, is dichloromethane (DCM).
[0043] The temperature for carrying out the dehydration reaction can also vary. Temperatures for the dehydration reaction can range from temperatures as low as, for example and without limitation, -40 C to higher temperatures, such as, for example and without limitation, 200 C, and can depend upon the leaving group.
In one embodiment, the temperature for carrying out the dehydration reaction, as shown in Step 3 of Scheme 1, is from -40 C to 50 C, and values in between. In another embodiment, the temperature can range from -20 C to 40 C, -15 C to C, -10 C to 25 C, 0 C to 25 C or 5 C to 25 C. In the embodiment shown in step 3 of Scheme 1, the reaction is initially performed at about 5 C and then allowed to continue at about 25 C.
The leaving group formed can vary and different leaving groups can be used for the elimination reaction to form the double bond. In one embodiment, the hydroxyl group is converted into a sulfonate-based leaving group, which can include, for example and without limitation, nonaflate, triflate, fluorosulfonate, tosylate, mesylate or besylate, as noted above. In another embodiment, as shown in Scheme 2 below, dehydration of the alcohol is performed in the presence of an acid, where H20 forms the leaving group. The sulfonate-based leaving groups can form good leaving groups and can help in improving the overall elimination reaction to form the double bond. In a further embodiment, the sulfonate-based leaving group is a mesylate.
[0042] The reaction conditions, such as, for example and without limitation, solvent, temperature and ratio of reagents, for the dehydration reaction can vary.
The solvent used in the nucleophilic reaction in Step 3 of Scheme 1, can include, for example, dichloromethane (DCM), toluene, tetrahydrofuran (THF), dimethyl ether (DME) or diethyl ether. In one embodiment, the solvent used in Step 3, as shown in Scheme 1, is dichloromethane (DCM).
[0043] The temperature for carrying out the dehydration reaction can also vary. Temperatures for the dehydration reaction can range from temperatures as low as, for example and without limitation, -40 C to higher temperatures, such as, for example and without limitation, 200 C, and can depend upon the leaving group.
In one embodiment, the temperature for carrying out the dehydration reaction, as shown in Step 3 of Scheme 1, is from -40 C to 50 C, and values in between. In another embodiment, the temperature can range from -20 C to 40 C, -15 C to C, -10 C to 25 C, 0 C to 25 C or 5 C to 25 C. In the embodiment shown in step 3 of Scheme 1, the reaction is initially performed at about 5 C and then allowed to continue at about 25 C.
[0044] Deprotection of compound 3b using an acid leads to compound 3c (Step 4). Step 5 involves acylation of the compound 3c using acetic anhydride to form compound 4. The reaction mixture can be quenched with an aqueous solution, for example water, to precipitate compound 4, which can be separated by filtration. Following the process as outlined in Scheme 1, compound 4 having purities of about 95% or greater can be achieved. Moreover, the process can avoid formation of the bis(steroidal) impurity that can be difficult to separate by purification.
[0045] Further to the above, methods of crystallization of compound 4 have been determined that can assist with purification and avoid use of column chromatography. Different solvent and solvent mixtures have been tested. In one embodiment, for example, the solvent system used for recrystallization is methanol, ethanol, isopropanol, isopropanol/water, toluene/heptanes or acetonitrile/water. In a further embodiment, different ratios of the solvent system have been determined for recrstallization. For example, methanol or ethanol was used for recrystallization from about 3 to 10 parts v/w and values in between like about 4 to 6 parts v/w or about 5 parts v/w. For solvent mixture systems, the ratio of the solvents can vary. For example, toluene/heptanes mixtures of about 0.5/3 v/v or about 1/2 v/v parts can be used; and for acetonitrile/water, mixtures of about 8/1 v/v, about 7/1, about 6/1 or about 5/1 parts can be used. In a further embodiment, the compound of formula 4 can be recrystallized using ethanol (5 v/w part) to provide a product having 98% purity or more, as disclosed herein, and lacking any bis(steroidal) contaminant. Further optimization using solvent and scale can improve purity.
[0046] The term "recrystallization" as used herein is not particularly limited and should be known to a skilled worker. The term "recrystallization" as used herein refers to a technique used to purify chemical compounds. The process can be carried out by dissolving both impurities and a compound in an appropriate solvent, either the desired compound or impurities can be coaxed out of solution, leaving the other behind. In the process disclosed herein, the compound of formula 3 or 4, along with impurities, is dissolved in the relevant solvent.
Dissolution can take place at elevated temperatures, including at the boiling point of the solvent used. This solvent is allowed to cool and crystallization of the compound of formula 3 or 4 to take place, followed by collection of the crystals.
[0047] Scheme 2, shown below, discloses alternate embodiments of carrying out the process for preparation of the compound of formula 4 in accordance with the specification, and where different R groups can be present and the reaction can be carried out in the presence or absence of a protecting group.
[0048] Scheme 2 also discloses alternative methods for carrying out the elimination reaction. For example, compound of formula 2c can be converted to the compound of formula 3c by use of an acid. The acid used in not particularly limited, and can include, for example and without limitation, hydrochloric acid, para-toluenesulfonic acid (PTSA) or acetic acid (AcOH). In a further embodiment, the acetylation and elimination reaction can be carried out concurrently by reaction of the compound of formula 2c with acetic anhydride to form compound of formula 4.
[0045] Further to the above, methods of crystallization of compound 4 have been determined that can assist with purification and avoid use of column chromatography. Different solvent and solvent mixtures have been tested. In one embodiment, for example, the solvent system used for recrystallization is methanol, ethanol, isopropanol, isopropanol/water, toluene/heptanes or acetonitrile/water. In a further embodiment, different ratios of the solvent system have been determined for recrstallization. For example, methanol or ethanol was used for recrystallization from about 3 to 10 parts v/w and values in between like about 4 to 6 parts v/w or about 5 parts v/w. For solvent mixture systems, the ratio of the solvents can vary. For example, toluene/heptanes mixtures of about 0.5/3 v/v or about 1/2 v/v parts can be used; and for acetonitrile/water, mixtures of about 8/1 v/v, about 7/1, about 6/1 or about 5/1 parts can be used. In a further embodiment, the compound of formula 4 can be recrystallized using ethanol (5 v/w part) to provide a product having 98% purity or more, as disclosed herein, and lacking any bis(steroidal) contaminant. Further optimization using solvent and scale can improve purity.
[0046] The term "recrystallization" as used herein is not particularly limited and should be known to a skilled worker. The term "recrystallization" as used herein refers to a technique used to purify chemical compounds. The process can be carried out by dissolving both impurities and a compound in an appropriate solvent, either the desired compound or impurities can be coaxed out of solution, leaving the other behind. In the process disclosed herein, the compound of formula 3 or 4, along with impurities, is dissolved in the relevant solvent.
Dissolution can take place at elevated temperatures, including at the boiling point of the solvent used. This solvent is allowed to cool and crystallization of the compound of formula 3 or 4 to take place, followed by collection of the crystals.
[0047] Scheme 2, shown below, discloses alternate embodiments of carrying out the process for preparation of the compound of formula 4 in accordance with the specification, and where different R groups can be present and the reaction can be carried out in the presence or absence of a protecting group.
[0048] Scheme 2 also discloses alternative methods for carrying out the elimination reaction. For example, compound of formula 2c can be converted to the compound of formula 3c by use of an acid. The acid used in not particularly limited, and can include, for example and without limitation, hydrochloric acid, para-toluenesulfonic acid (PTSA) or acetic acid (AcOH). In a further embodiment, the acetylation and elimination reaction can be carried out concurrently by reaction of the compound of formula 2c with acetic anhydride to form compound of formula 4.
/ \ N\
/ N
MsCI
Et3N
110. DCM
Oil ROSS ROSS
SO SO
R=TBS 2b R=TBS 3b N
O. B Ha r Dioxane 010 nB.ILi r RO / \ N / \ N
R=H, Po, T I Ha or 1 O. OH TpsA
50 Ole HD HO
2c 3c Ao20 1 Ac20 pyricine pyridne / \ N \
/ N
OH [Visa 01 Et3Nm Oil O. Ole Pc0 ADO
2d 4 Scheme 2 [0049] The organic solvent used in the reactions described herein is not particularly limited and should be known to a person of skill in the art or can be determined. The particular solvent used would depend upon the reactants and the reaction being carried out, to allow the reaction to proceed. Similarly, the reaction temperature used in the process steps disclosed herein is not particularly limited and should be known to a skilled worker or can be determined. The reaction temperature can depend upon a number of factors including reagents, solvent and presence of catalyst.
[0050] The process as disclosed herein can lead to different intermediates that can be useful for the preparation of the compound of formula 4.
Therefore, in another aspect the specification discloses compounds of formula 2, where Ar is an aryl group, R is H or an alcohol protecting group and R' is H, an alcohol protecting group or Rl together with the oxygen to which it is attached forms a leaving group.
Ar Oe RO
10 [0051] In a further aspect, the specification relates to the compound of formula 3, where Ar is an aryl group; and R is a silyl-based protecting group.
Ar OB
RO
/ N
MsCI
Et3N
110. DCM
Oil ROSS ROSS
SO SO
R=TBS 2b R=TBS 3b N
O. B Ha r Dioxane 010 nB.ILi r RO / \ N / \ N
R=H, Po, T I Ha or 1 O. OH TpsA
50 Ole HD HO
2c 3c Ao20 1 Ac20 pyricine pyridne / \ N \
/ N
OH [Visa 01 Et3Nm Oil O. Ole Pc0 ADO
2d 4 Scheme 2 [0049] The organic solvent used in the reactions described herein is not particularly limited and should be known to a person of skill in the art or can be determined. The particular solvent used would depend upon the reactants and the reaction being carried out, to allow the reaction to proceed. Similarly, the reaction temperature used in the process steps disclosed herein is not particularly limited and should be known to a skilled worker or can be determined. The reaction temperature can depend upon a number of factors including reagents, solvent and presence of catalyst.
[0050] The process as disclosed herein can lead to different intermediates that can be useful for the preparation of the compound of formula 4.
Therefore, in another aspect the specification discloses compounds of formula 2, where Ar is an aryl group, R is H or an alcohol protecting group and R' is H, an alcohol protecting group or Rl together with the oxygen to which it is attached forms a leaving group.
Ar Oe RO
10 [0051] In a further aspect, the specification relates to the compound of formula 3, where Ar is an aryl group; and R is a silyl-based protecting group.
Ar OB
RO
[0052] In a still further aspect, the specification relates to abiraterone acetate having a purity of 95 /o, 96 /o, 97 /o, 193 /o, 1919 /o, 199.5% or 99.9%, as determined by HPLC. Further, the specification discloses abiraterone acetate being substantially free of the bis(steroidal) contaminant.
[0053] In still another aspect, the specification relates to the compound of formula 3 having a purity of ?95%, ?96%, ?97%, ?98%, ?99%, ?99.5% or ?99.9%, as determined by HPLC.
[0054] In another further aspect, the specification relates to compound of formula 2 having a purity of ?950/0, ?960/0, 970/(:), 980/(:), 99%, 99.5% or 199.9 /0, as determined by HPLC.
EXAMPLE EMBODIMENTS
[0055] Disclosed herein below are example embodiments of the specification, which are not intended to be limiting of the invention as described and claimed herein.
[0056] EXAMPLE 1: Compound lb [0057] A 250 ml three necks round bottom flask equipped with a magnetic stirrer, thermometer and nitrogen inlet was charged with compound la (60g 208mmole), dimethylformamide (DMF) (600m1), tert-butyldimethylsilyl chloride (TBSCI) (38g 250mmol), N,N-dimethylamino pyridine (DMAP) (5g 42mmole) and triethylamine (Et3N) (32g, 312nnmol). The suspension is stirred 24 hr. TLC
analysis indicated the depletion of compound la (Hep: Et0Ac 1:1 AMCS). The reaction mixture is poured in water (3L) and agitated for 1.5hr. The solid product is collected by filtration and washed with water (2L) and dried at high vacuum at 45 C for hour to give 83g of compound lb off white solid (Quantitative yield). NMR
confirmed structure.
[0053] In still another aspect, the specification relates to the compound of formula 3 having a purity of ?95%, ?96%, ?97%, ?98%, ?99%, ?99.5% or ?99.9%, as determined by HPLC.
[0054] In another further aspect, the specification relates to compound of formula 2 having a purity of ?950/0, ?960/0, 970/(:), 980/(:), 99%, 99.5% or 199.9 /0, as determined by HPLC.
EXAMPLE EMBODIMENTS
[0055] Disclosed herein below are example embodiments of the specification, which are not intended to be limiting of the invention as described and claimed herein.
[0056] EXAMPLE 1: Compound lb [0057] A 250 ml three necks round bottom flask equipped with a magnetic stirrer, thermometer and nitrogen inlet was charged with compound la (60g 208mmole), dimethylformamide (DMF) (600m1), tert-butyldimethylsilyl chloride (TBSCI) (38g 250mmol), N,N-dimethylamino pyridine (DMAP) (5g 42mmole) and triethylamine (Et3N) (32g, 312nnmol). The suspension is stirred 24 hr. TLC
analysis indicated the depletion of compound la (Hep: Et0Ac 1:1 AMCS). The reaction mixture is poured in water (3L) and agitated for 1.5hr. The solid product is collected by filtration and washed with water (2L) and dried at high vacuum at 45 C for hour to give 83g of compound lb off white solid (Quantitative yield). NMR
confirmed structure.
[0058] EXAMPLE 2: Compound 2b [0059] A 500 ml three neck round bottom flask equipped with a magnetic stirrer, thermometer and nitrogen inlet was charged with 3-bromopyridine (19.6g 124mmol) and toluene (100 ml). The solution was cooled to -65 C. With agitation, 2.5M n-butyl lithium (nBuLi) in hexanes (5oml, 124mmol) was charged while maintaining a temperature of reaction less than -60 C. The mixture was then agitated at same temperature for 1.5 hours. Charged with a solution of compound lb (5g, 12.4mmol) in toluene (100 ml). The brown reaction mixture was agitated at for -65 C 1 hour. TLC analysis indicated formation of compound 2b (Hep:Et0Ac 1:1 UV, AMCS) The mixture was quenched with the mixture of 12% of NaC1 solution (200m1). The reaction mixture was warm to10 C. The mixture was extracted with 200m1 of methy tert-butyl ether (MTBE). Organic layer was separated and concentrated to dryness. The crude was triturated with acetonitrile (100m1). Solid product was collected by filtration and washed with acetonitrile (40m1) and dried at high vacuum oven at 45 C for 16 hours to give compound 2b as an off white solid 4.7g (79% yield). NMR and MS confirmed structure.
[0060] EXAMPLE 3: Compound 3b [0061] A 250 ml three neck round bottom flask with a magnetic stirrer and nitrogen inlet was charged with compound 2b (4.5g, 9.3 mmol) and dichloromethane (DCM) (90 ml). The solution was cooled to 5 C. With agitation, triethylamine (Et3N) (9.5g 93mmol) and mesyl chloride (MsC1) (5.4g 47mmol) was charged. The mixture was then agitated at same temperature for 1 hour and ambient temperature for 1 hour. TLC analysis indicated the depletion of compound 2b (Et0Ac UV and AMCS). The reaction solution was quenched with sat NaHCO3.
Separated organic is dried with MgSO4 and separated and concentrated to dryness.
The crude was purified with silica gel (100g) with Biotage. Eluted with ethyl acetate (Et0Ac) and Heptane 10% to 50%. Pure fraction was collected and concentrated to dryness to give compound 3b as a white solid 3g (69% yield). NMR and MS
confirmed structure.
[0062] EXAMPLE 4: Compound 3c [0063] A 100 ml one neck round bottom flask with a magnetic stirrer was charged with compound 3b (2.5g, 5.4 mmol), 1,4-dioxane (25 ml), methanol (Me0H) (12.5m1) and HC14M in 1,4-dioxane (5.4 ml 22mmol). The suspension was agitated for 0.5 hour at ambient temperature. The reaction mixture was turn to solution. Continue agitating for 1 hour the solution was turn to suspension.
The mixture was then agitated for another 3 hours. TLC analysis indicated the depletion of compound 3b (Hep:Et0Ac 1:1 UV and AMCS). The solution concentrated to dryness. The crude was triturated with 1,4-dioxane(25m1) for lhour. The solid product was collected by filtration and washed with 1,4-dioxane (10m1) and dried at high vacuum oven at 45 C for 16 hours to give compound 3c as a white solid 2.1g (quantitative yield). NMR and MS confirmed structure.
[0064] EXAMPLE 5: Compound 4 [0065] A 100 ml one neck round bottom flask with a magnetic stirrer was charged with compound 3c (2.0g, 5.7 mmol), pyridine (20m1) and acetyl anhydride (2.7 ml 29mmol). The suspension was agitated for 0.5 hour at ambient temperature. The reaction mixture was turn to solution. The reaction solution was then agitated for another 1.5 hours. TLC analysis indicated the depletion of compound 3c (Et0Ac UV and AMCS). The reaction solution was quenched with water (40m1) at ice bath. The temperature was remained under 15 C. After quench, the white solid product was precipitated out. The mixture was agitated at ice bath for 2 hours. The solid product was collected by filtration and washed with water (20m1) and dried at high vacuum oven at 45 C for 72 hours to give compound 4 a white solid 1.9g (85% yield, 95% purity by HPLC). NMR and MS
confirmed structure.
[0060] EXAMPLE 3: Compound 3b [0061] A 250 ml three neck round bottom flask with a magnetic stirrer and nitrogen inlet was charged with compound 2b (4.5g, 9.3 mmol) and dichloromethane (DCM) (90 ml). The solution was cooled to 5 C. With agitation, triethylamine (Et3N) (9.5g 93mmol) and mesyl chloride (MsC1) (5.4g 47mmol) was charged. The mixture was then agitated at same temperature for 1 hour and ambient temperature for 1 hour. TLC analysis indicated the depletion of compound 2b (Et0Ac UV and AMCS). The reaction solution was quenched with sat NaHCO3.
Separated organic is dried with MgSO4 and separated and concentrated to dryness.
The crude was purified with silica gel (100g) with Biotage. Eluted with ethyl acetate (Et0Ac) and Heptane 10% to 50%. Pure fraction was collected and concentrated to dryness to give compound 3b as a white solid 3g (69% yield). NMR and MS
confirmed structure.
[0062] EXAMPLE 4: Compound 3c [0063] A 100 ml one neck round bottom flask with a magnetic stirrer was charged with compound 3b (2.5g, 5.4 mmol), 1,4-dioxane (25 ml), methanol (Me0H) (12.5m1) and HC14M in 1,4-dioxane (5.4 ml 22mmol). The suspension was agitated for 0.5 hour at ambient temperature. The reaction mixture was turn to solution. Continue agitating for 1 hour the solution was turn to suspension.
The mixture was then agitated for another 3 hours. TLC analysis indicated the depletion of compound 3b (Hep:Et0Ac 1:1 UV and AMCS). The solution concentrated to dryness. The crude was triturated with 1,4-dioxane(25m1) for lhour. The solid product was collected by filtration and washed with 1,4-dioxane (10m1) and dried at high vacuum oven at 45 C for 16 hours to give compound 3c as a white solid 2.1g (quantitative yield). NMR and MS confirmed structure.
[0064] EXAMPLE 5: Compound 4 [0065] A 100 ml one neck round bottom flask with a magnetic stirrer was charged with compound 3c (2.0g, 5.7 mmol), pyridine (20m1) and acetyl anhydride (2.7 ml 29mmol). The suspension was agitated for 0.5 hour at ambient temperature. The reaction mixture was turn to solution. The reaction solution was then agitated for another 1.5 hours. TLC analysis indicated the depletion of compound 3c (Et0Ac UV and AMCS). The reaction solution was quenched with water (40m1) at ice bath. The temperature was remained under 15 C. After quench, the white solid product was precipitated out. The mixture was agitated at ice bath for 2 hours. The solid product was collected by filtration and washed with water (20m1) and dried at high vacuum oven at 45 C for 72 hours to give compound 4 a white solid 1.9g (85% yield, 95% purity by HPLC). NMR and MS
confirmed structure.
[0066] EXAMPLE 6: Purification of Compound 4 by crystallization [0067] Charge a round bottom flask with 1.0 g of compound 4 and 5 to 10 mL
of ethanol. With agitation, heat the mixture to reflux until clear solution is attained.
Cool the solution gradually to 0 -25 C. Collect crystallized product by filtration, dry under nitrogen flow until constant weight is achieved. HPLC analysis indicates purity of 98%.
[0068] EXAMPLE 7: Preparation of compound lb o o te MSG/ DMF
.._ opie Et3N O.
HO TBSO
la lb [0069] A 1L three necks round bottom flask equipped with a over head stirrer, thermometer and nitrogen inlet was charged with compound la (50g, 173mmole), tert-butyl dimethyl silyl chloride (TBSCI) (31.4g 208mmol), dimethylformamide (DMF) (375m1) and triethylamine (Et3N) (26g, 260mmol). The suspension is heated up to 50 C, stirred 3 hr. HPLC analysis indicated the depletion of compound la.
The reaction mixture was cooled to 5 C and quenched the reaction mixture with water (375 ml). The temperature of the mixture was raised to 15 C and then agitated at ambient temperature for 2hr. The solid product is collected by filtration and washed with water (750m1) and dried at high vacuum at 45 C for 24 hour to give 69g of compound lb off white solid (99% yield). NMR confirmed structure.
[0070] EXAMPLE 8: Preparation of compound 2b N
OH
0.O. Br O. nBuLifTd uene O.
TBSO TBSO
1b 2b [0071] A 2L three neck round bottom flask equipped with a overhead stirrer, thermometer, dropping funnel and nitrogen inlet was charged with toluene (500 ml) and cooled to -65 C. With agitation, 2.5M n-butyl lithium (nBuLi) in hexanes (225m1, 550mmol) was charged while maintaining a temperature of reaction less than -60 C. Addition took 50 min. Then 3-bromopyridine (59g 373mmo1) in toluene (100 ml) was charged over 2 hr. The solution was agitated at -65 C for 0.5 hr.
Prepared a solution of compound lb (50g, 124mmol) in toluene (400 ml) and charged to the reaction solution over 2 hr. The light brown reaction mixture was agitated at for -65 C 0.5 hour. TLC analysis indicated formation of compound 2b (Hep:Et0Ac 1:1 UV, AMCS) The mixture was warmed up to -35 C and quenched with the water (500m1). The reaction mixture was then warm to10 C. Organic layer was separated and the aqueous is extracted with toluene (500m1).
Combined organic was washed with water (500m1). Separated organic layer was concentrated to 250 ml. Charged with heptane (750m1). The mixture was concentrated to 250 ml and then charged with heptane (750m1). Repeated this procedure for another time. At the last, to the 250 ml mixture, charged with heptane (250m1). The mixture was agitated at ambient temperature for 1 hr. Solid product was collected by filtration and washed with heptane (150m1) and dried at high vacuum oven at 45 C for 16 hours to give compound 2b a off white solid 46g (77% yield). NMR
and MS confirmed structure.
[0072] EXAMPLE 9: Preparation of compound 4a - N
/ \ N
CH
O.1) MsCI, Et3N, EX
_______________________________________________ 0- O.
50 2) Conc HO/THF O.
TESO HO
2b 3c / \ N
4c20 ______________________ >
Pyridine O.
O.
Pc 4a [0073] A solution of compound 2b (200 g, 415mmol, 1 equiv) in CH2Cl2 (DCM) (1600 mL, 8 parts) in a 5L 3-neck round-bottom flask equipped with a dropping funnel was flushed with nitrogen (N2) for 5 min. The solution was cooled to 5 C and triethyl amine (578.5 mL, 4151mmol, 10 equiv) was added slowly over 30 min and was stirred at 5 C for 15 minutes. Then mesyl chloride (MsCI) (161.3 mL, 2075 mmol, 5 equiv) was added drop wise over 45 min by controlling the temperature below12 C. The reaction mixture was then stirred at 5 C for 1.5 -h. The ice-bath was removed and the reaction mixture was stirred to room temperature for 12 h. DI water (600 mL 3 parts) was added to the reaction mixture and stirred for 30 minutes, separated out the DCM layer. The DCM layer is then washed with DI water (600 mL, 3 parts) and was concentrated on a rotovap (bath @35 C) down to 1000 mL (5 parts). Then solvent exchanged to tetrahydrofuran (THF) by charging THF (2x2000 mL, 10 parts each) and concentrated to 1000 mL
(5 parts).The concentrated reaction mixture was transferred into a 5L 3-neck round-bottom flask equipped with a dropping funnel. Charged THF (2000 mL, 10 parts) at room temperature and slowly added concentrated hydrochloric acid (76 mL, 2.2 equiv) from the dropping funnel over lhour. Agitated the reaction mixture (light-brown suspension) at room temperature for 2 hours and was filtered.
Washed with THF (2x1000 mL, 5 parts each). Dried the solids at room temperature under suction with nitrogen atmosphere to afford compound 3c (170.3 g).
[0074] To a suspension of compound 3c (170 g, 440.8 mmol) in pyridine (680 mL, 4 parts) in a 5L 3-neck round-bottom flask equipped with a dropping funnel was added acetic anhydride solution (208.5 mL, 2204 mmo1,5 equiv) at room temperature slowly from an addition funnel over 30 minutes. The mixture was stirred at room temperature for 4 h. Cooled the reaction mixture to 50C and D.I.
water (1700 mL, 10 parts) was added slowly by controlling the temperature below C. Agitated the reaction mixture at 5 C for 3 h and the solids were filtered, washed with DI water (2x 850 mL, 5 parts each) and dried at room temperature 15 under suction for 18 h and then in a vacuum oven at 450C under vacuum for 24 h to afford crude compound 4a (140.2 g).
[0075] EXAMPLE 10: Recrystallization of compound 4a [0076] 5g of the crude compound 4 (where Ar is 3-pyridinyl) was dissolved in isopropanol (IPA) (100 mL, 20 parts) and was filtered through a celite pad, washed the celite pad with IPA (15 mL, 3parts). The filtered IPA solution of compound 4 is then passed through a carbon cartridge filter (SUPRACAP AKS-1 60D, PALL
FILTER).
Washed the carbon filter with IPA (75mL, 15 parts). Combined all the IPA
filtrates and washes and was concentrated to 30 mL (6 parts) on a rotovap (bath@40 C).
Charged DI water 30mL (6 parts) and heated the reaction mixture to 80 C to dissolve all the solids and maintained for 1 h at 80 C. Then cooled to room temperature and maintained for 12 h and then cooled to 5 C and maintained for h. The white solids were filtered, washed with 1:1 IPA/water mixture (10 mL, 2 parts) and dried in a vacuum oven at 450C under vacuum for 24 h to afford pure compound 4a (3.34 g). HPLC analysis indicates purity of 99.7%.
of ethanol. With agitation, heat the mixture to reflux until clear solution is attained.
Cool the solution gradually to 0 -25 C. Collect crystallized product by filtration, dry under nitrogen flow until constant weight is achieved. HPLC analysis indicates purity of 98%.
[0068] EXAMPLE 7: Preparation of compound lb o o te MSG/ DMF
.._ opie Et3N O.
HO TBSO
la lb [0069] A 1L three necks round bottom flask equipped with a over head stirrer, thermometer and nitrogen inlet was charged with compound la (50g, 173mmole), tert-butyl dimethyl silyl chloride (TBSCI) (31.4g 208mmol), dimethylformamide (DMF) (375m1) and triethylamine (Et3N) (26g, 260mmol). The suspension is heated up to 50 C, stirred 3 hr. HPLC analysis indicated the depletion of compound la.
The reaction mixture was cooled to 5 C and quenched the reaction mixture with water (375 ml). The temperature of the mixture was raised to 15 C and then agitated at ambient temperature for 2hr. The solid product is collected by filtration and washed with water (750m1) and dried at high vacuum at 45 C for 24 hour to give 69g of compound lb off white solid (99% yield). NMR confirmed structure.
[0070] EXAMPLE 8: Preparation of compound 2b N
OH
0.O. Br O. nBuLifTd uene O.
TBSO TBSO
1b 2b [0071] A 2L three neck round bottom flask equipped with a overhead stirrer, thermometer, dropping funnel and nitrogen inlet was charged with toluene (500 ml) and cooled to -65 C. With agitation, 2.5M n-butyl lithium (nBuLi) in hexanes (225m1, 550mmol) was charged while maintaining a temperature of reaction less than -60 C. Addition took 50 min. Then 3-bromopyridine (59g 373mmo1) in toluene (100 ml) was charged over 2 hr. The solution was agitated at -65 C for 0.5 hr.
Prepared a solution of compound lb (50g, 124mmol) in toluene (400 ml) and charged to the reaction solution over 2 hr. The light brown reaction mixture was agitated at for -65 C 0.5 hour. TLC analysis indicated formation of compound 2b (Hep:Et0Ac 1:1 UV, AMCS) The mixture was warmed up to -35 C and quenched with the water (500m1). The reaction mixture was then warm to10 C. Organic layer was separated and the aqueous is extracted with toluene (500m1).
Combined organic was washed with water (500m1). Separated organic layer was concentrated to 250 ml. Charged with heptane (750m1). The mixture was concentrated to 250 ml and then charged with heptane (750m1). Repeated this procedure for another time. At the last, to the 250 ml mixture, charged with heptane (250m1). The mixture was agitated at ambient temperature for 1 hr. Solid product was collected by filtration and washed with heptane (150m1) and dried at high vacuum oven at 45 C for 16 hours to give compound 2b a off white solid 46g (77% yield). NMR
and MS confirmed structure.
[0072] EXAMPLE 9: Preparation of compound 4a - N
/ \ N
CH
O.1) MsCI, Et3N, EX
_______________________________________________ 0- O.
50 2) Conc HO/THF O.
TESO HO
2b 3c / \ N
4c20 ______________________ >
Pyridine O.
O.
Pc 4a [0073] A solution of compound 2b (200 g, 415mmol, 1 equiv) in CH2Cl2 (DCM) (1600 mL, 8 parts) in a 5L 3-neck round-bottom flask equipped with a dropping funnel was flushed with nitrogen (N2) for 5 min. The solution was cooled to 5 C and triethyl amine (578.5 mL, 4151mmol, 10 equiv) was added slowly over 30 min and was stirred at 5 C for 15 minutes. Then mesyl chloride (MsCI) (161.3 mL, 2075 mmol, 5 equiv) was added drop wise over 45 min by controlling the temperature below12 C. The reaction mixture was then stirred at 5 C for 1.5 -h. The ice-bath was removed and the reaction mixture was stirred to room temperature for 12 h. DI water (600 mL 3 parts) was added to the reaction mixture and stirred for 30 minutes, separated out the DCM layer. The DCM layer is then washed with DI water (600 mL, 3 parts) and was concentrated on a rotovap (bath @35 C) down to 1000 mL (5 parts). Then solvent exchanged to tetrahydrofuran (THF) by charging THF (2x2000 mL, 10 parts each) and concentrated to 1000 mL
(5 parts).The concentrated reaction mixture was transferred into a 5L 3-neck round-bottom flask equipped with a dropping funnel. Charged THF (2000 mL, 10 parts) at room temperature and slowly added concentrated hydrochloric acid (76 mL, 2.2 equiv) from the dropping funnel over lhour. Agitated the reaction mixture (light-brown suspension) at room temperature for 2 hours and was filtered.
Washed with THF (2x1000 mL, 5 parts each). Dried the solids at room temperature under suction with nitrogen atmosphere to afford compound 3c (170.3 g).
[0074] To a suspension of compound 3c (170 g, 440.8 mmol) in pyridine (680 mL, 4 parts) in a 5L 3-neck round-bottom flask equipped with a dropping funnel was added acetic anhydride solution (208.5 mL, 2204 mmo1,5 equiv) at room temperature slowly from an addition funnel over 30 minutes. The mixture was stirred at room temperature for 4 h. Cooled the reaction mixture to 50C and D.I.
water (1700 mL, 10 parts) was added slowly by controlling the temperature below C. Agitated the reaction mixture at 5 C for 3 h and the solids were filtered, washed with DI water (2x 850 mL, 5 parts each) and dried at room temperature 15 under suction for 18 h and then in a vacuum oven at 450C under vacuum for 24 h to afford crude compound 4a (140.2 g).
[0075] EXAMPLE 10: Recrystallization of compound 4a [0076] 5g of the crude compound 4 (where Ar is 3-pyridinyl) was dissolved in isopropanol (IPA) (100 mL, 20 parts) and was filtered through a celite pad, washed the celite pad with IPA (15 mL, 3parts). The filtered IPA solution of compound 4 is then passed through a carbon cartridge filter (SUPRACAP AKS-1 60D, PALL
FILTER).
Washed the carbon filter with IPA (75mL, 15 parts). Combined all the IPA
filtrates and washes and was concentrated to 30 mL (6 parts) on a rotovap (bath@40 C).
Charged DI water 30mL (6 parts) and heated the reaction mixture to 80 C to dissolve all the solids and maintained for 1 h at 80 C. Then cooled to room temperature and maintained for 12 h and then cooled to 5 C and maintained for h. The white solids were filtered, washed with 1:1 IPA/water mixture (10 mL, 2 parts) and dried in a vacuum oven at 450C under vacuum for 24 h to afford pure compound 4a (3.34 g). HPLC analysis indicates purity of 99.7%.
EMBODIMENTS
[0077] 1. A process for preparation of the compound of formula 4, the process comprising:
0 Ar ORi lee O.
OS _Jo.. OpOp RO RO
Ar Ar SO SO
RO MO
[0078] nucleophillic addition reaction of the compound of formula 1 with a compound of formula Ar-M to form the compound of formula 2;
[0079] dehydrating the compound of formula 2 to form the compound of formula 3 or 4;
[0080] optionally, deprotecting the compound of formula 3; and [0081] optionally, acylating the compound of formula 3 to form the compound of formula 4, [0082] wherein [0083] R is H or an alcohol protecting group;
[0084] R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group;
[0085] M is alkali metal, alkali earth metal or a transition metal of group 11 or 12;
[0086] Ar is an aryl group and [0087] Ac is an acyl group.
[0088] 2. The process according to embodiment 1, wherein Ar is a heteroaryl group.
[0089] 3. The process according to embodiment 1, wherein Ar is pyridinyl.
[0090] 4. The process according to embodiment 1, wherein Ar is 3-substituted pyridinyl.
[0091] 5. The process according to any one of embodiments 1 to 4, wherein R is an alcohol protecting group.
[0092] 6. The process according to any one of embodiments 1 to 4, wherein R is an alcohol protecting group and the alcohol protecting group is acetyl.
[0093] 7. The process according to any one of embodiments 1 to 4, wherein R is an alcohol protecting group and the alcohol protecting group is a silyl-based protecting group.
[0094] 8. The process according to embodiment 7, wherein the silyl-based protecting group is tert-butyldimethylsilyl (TBDMS or TBS).
[0095] 9. The process according to any one of embodiments 1 to 8, wherein M is alkali metal.
[0096] 10. The process according to embodiment 9, wherein the alkali metal is Li.
[0097] 11. The process according to any one of embodiments 1 to 10, wherein R1 is H.
[0077] 1. A process for preparation of the compound of formula 4, the process comprising:
0 Ar ORi lee O.
OS _Jo.. OpOp RO RO
Ar Ar SO SO
RO MO
[0078] nucleophillic addition reaction of the compound of formula 1 with a compound of formula Ar-M to form the compound of formula 2;
[0079] dehydrating the compound of formula 2 to form the compound of formula 3 or 4;
[0080] optionally, deprotecting the compound of formula 3; and [0081] optionally, acylating the compound of formula 3 to form the compound of formula 4, [0082] wherein [0083] R is H or an alcohol protecting group;
[0084] R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group;
[0085] M is alkali metal, alkali earth metal or a transition metal of group 11 or 12;
[0086] Ar is an aryl group and [0087] Ac is an acyl group.
[0088] 2. The process according to embodiment 1, wherein Ar is a heteroaryl group.
[0089] 3. The process according to embodiment 1, wherein Ar is pyridinyl.
[0090] 4. The process according to embodiment 1, wherein Ar is 3-substituted pyridinyl.
[0091] 5. The process according to any one of embodiments 1 to 4, wherein R is an alcohol protecting group.
[0092] 6. The process according to any one of embodiments 1 to 4, wherein R is an alcohol protecting group and the alcohol protecting group is acetyl.
[0093] 7. The process according to any one of embodiments 1 to 4, wherein R is an alcohol protecting group and the alcohol protecting group is a silyl-based protecting group.
[0094] 8. The process according to embodiment 7, wherein the silyl-based protecting group is tert-butyldimethylsilyl (TBDMS or TBS).
[0095] 9. The process according to any one of embodiments 1 to 8, wherein M is alkali metal.
[0096] 10. The process according to embodiment 9, wherein the alkali metal is Li.
[0097] 11. The process according to any one of embodiments 1 to 10, wherein R1 is H.
[0098] 12. The process according to any one of embodiments 1 to 10, wherein RI- together with the oxygen to which it is attached forms a leaving group.
[0099] 13. The process according to any one of embodiments 1 to 10, wherein RI- together with the oxygen to which it is attached forms a leaving group and the leaving group is nnesylate or tosylate.
[00100] 14. The process according to any one of embodiments 1 to 13, wherein the step of dehydrating the compound of formula 2 is carried out in the presence of an acid.
[00101] 15. The process according to embodiment 14, wherein the acid is hydrochloric acid (HCI) or p-toluene sulfonic acid (pTSA).
[00102] 16. The process according to any one of embodiments 1 to 13, wherein the step of dehydrating the compound of formula 2 is carried out in the presence of a base.
[00103] 17. The process according to embodiment 16, wherein the base is triethylamine (TEA).
[00104] 18. The process according to any one of embodiments 1 to 17, wherein the step of deprotecting the compound of formula 3 is carried out in the presence of an acid.
[00105] 19. The process according to any one of embodiments 1 to 17, wherein the step of deprotecting the compound of formula 3 is carried out in using a fluoride source.
[00106] 20. The process according to any one of embodiments 1 to 19, wherein the step of acylating comprises acetylating the compound of formula 3.
[00107] 21. The process according to any one of embodiments 1 to 20, wherein the process comprises forming the compound of formula 4a .----N
\ /
OB
O.
o--) 4a .
[00108] 22. The compound of formula 2, Ar OR' Oe RO
[00109] wherein 5 [00110] Ar is an aryl group;
[00111] R is H or an alcohol protecting group; and [00112] R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group.
[00113] 23. The compound of embodiment 22, wherein Ar is pyridinyl.
10 [00114] 24. The compound of embodiment 23, wherein the compound of formula 2 is a compound of formula 2a / \N
OR' Oe ROSS
2a [00115] 25. The compound of any one of embodiments 22 to 24, wherein Rl is H.
[00116] 26. The compound of any one of embodiments 22 to 24, wherein together with the oxygen to which it is attached forms a leaving group.
[00117] 27. The compound of any one of embodiments 22 to 26, wherein R
is acetyl.
[00118] 28. The compound of any one of embodiments 22 to 26, wherein R
is a silyl-based protecting group.
[00119] 29. The compound of formula 3, Ar O.
RO
[00120] wherein [00121] Ar is an aryl group; and [00122] R is a silyl-based protecting group.
[00123] 30. The compound of embodiment 29, wherein Ar is pyridinyl.
[00124] 31. The compound of embodiment 29 or 30, wherein the compound is the compound of formula 3a .---N
\/
0.
RD O.
3a .
[00125] 32. The compound of any one of embodiments 29 to 31, wherein the silyl-based protecting group is tert-butyldimethylsilyl (TBDMS or TBS).
[00126] 33. Abiraterone acetate having a purity of ?95 /0, 96 /0, 97 /0, 198 /0, 199 /0, 199.5% or 199.9(:)/0, as determined by HPLC.
[00127] 34. The compound of formula 3 having a purity of 950/c), 9E.cYc), ?97%, ?98%, ?99c)/0, ?99.5% or ?99.9%, as determined by HPLC.
[00128] 35. The compound of formula 2 having a purity of 95 /c), 96 /(:), 97c1/0, 98c)/0, 99 /0, 99.5% or 99.9%, as determined by HPLC.
[00129] 36. A process for purification of the compound of formula 3 or 4, Ar A r O.
ROSS
At 1:30 4 [00130] wherein R is H or an alcohol protecting group; Ar is an aryl or heteroaryl group and Ac is an acyl group;
[00131] the process containing the step of recrstallizing the compound of formula 3 or 4 with a solvent selected from the group consisting of methanol, ethanol, isopropanol, isopropanol/water, toluene/heptanes and acetonitrile/water.
[00132] 37. The process of embodiment 36, wherein the solvent is methanol, ethanol or isopropanol.
[00133] 38. The process of embodiment 37, wherein the solvent used is 3 to 10 parts v/w of the compound of formula 3 or 4.
[00134] 39. The process of embodiment 36, wherein the solvent is isopropanol/water, toluene/heptanes and acetonitrile/water.
[00135] 40. The process of embodiment 39, wherein the solvent is toluene/heptanes and the solvent used is 0.5/3 to 1/2 parts v/w of the compound of formula 3 or 4.
[00136] 41. The process of embodiment 39, wherein the solvent is acetonitrile/water and the solvent used is 8/1 to 5/1 parts v/w of the compound of formula 3 or 4.
[0099] 13. The process according to any one of embodiments 1 to 10, wherein RI- together with the oxygen to which it is attached forms a leaving group and the leaving group is nnesylate or tosylate.
[00100] 14. The process according to any one of embodiments 1 to 13, wherein the step of dehydrating the compound of formula 2 is carried out in the presence of an acid.
[00101] 15. The process according to embodiment 14, wherein the acid is hydrochloric acid (HCI) or p-toluene sulfonic acid (pTSA).
[00102] 16. The process according to any one of embodiments 1 to 13, wherein the step of dehydrating the compound of formula 2 is carried out in the presence of a base.
[00103] 17. The process according to embodiment 16, wherein the base is triethylamine (TEA).
[00104] 18. The process according to any one of embodiments 1 to 17, wherein the step of deprotecting the compound of formula 3 is carried out in the presence of an acid.
[00105] 19. The process according to any one of embodiments 1 to 17, wherein the step of deprotecting the compound of formula 3 is carried out in using a fluoride source.
[00106] 20. The process according to any one of embodiments 1 to 19, wherein the step of acylating comprises acetylating the compound of formula 3.
[00107] 21. The process according to any one of embodiments 1 to 20, wherein the process comprises forming the compound of formula 4a .----N
\ /
OB
O.
o--) 4a .
[00108] 22. The compound of formula 2, Ar OR' Oe RO
[00109] wherein 5 [00110] Ar is an aryl group;
[00111] R is H or an alcohol protecting group; and [00112] R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group.
[00113] 23. The compound of embodiment 22, wherein Ar is pyridinyl.
10 [00114] 24. The compound of embodiment 23, wherein the compound of formula 2 is a compound of formula 2a / \N
OR' Oe ROSS
2a [00115] 25. The compound of any one of embodiments 22 to 24, wherein Rl is H.
[00116] 26. The compound of any one of embodiments 22 to 24, wherein together with the oxygen to which it is attached forms a leaving group.
[00117] 27. The compound of any one of embodiments 22 to 26, wherein R
is acetyl.
[00118] 28. The compound of any one of embodiments 22 to 26, wherein R
is a silyl-based protecting group.
[00119] 29. The compound of formula 3, Ar O.
RO
[00120] wherein [00121] Ar is an aryl group; and [00122] R is a silyl-based protecting group.
[00123] 30. The compound of embodiment 29, wherein Ar is pyridinyl.
[00124] 31. The compound of embodiment 29 or 30, wherein the compound is the compound of formula 3a .---N
\/
0.
RD O.
3a .
[00125] 32. The compound of any one of embodiments 29 to 31, wherein the silyl-based protecting group is tert-butyldimethylsilyl (TBDMS or TBS).
[00126] 33. Abiraterone acetate having a purity of ?95 /0, 96 /0, 97 /0, 198 /0, 199 /0, 199.5% or 199.9(:)/0, as determined by HPLC.
[00127] 34. The compound of formula 3 having a purity of 950/c), 9E.cYc), ?97%, ?98%, ?99c)/0, ?99.5% or ?99.9%, as determined by HPLC.
[00128] 35. The compound of formula 2 having a purity of 95 /c), 96 /(:), 97c1/0, 98c)/0, 99 /0, 99.5% or 99.9%, as determined by HPLC.
[00129] 36. A process for purification of the compound of formula 3 or 4, Ar A r O.
ROSS
At 1:30 4 [00130] wherein R is H or an alcohol protecting group; Ar is an aryl or heteroaryl group and Ac is an acyl group;
[00131] the process containing the step of recrstallizing the compound of formula 3 or 4 with a solvent selected from the group consisting of methanol, ethanol, isopropanol, isopropanol/water, toluene/heptanes and acetonitrile/water.
[00132] 37. The process of embodiment 36, wherein the solvent is methanol, ethanol or isopropanol.
[00133] 38. The process of embodiment 37, wherein the solvent used is 3 to 10 parts v/w of the compound of formula 3 or 4.
[00134] 39. The process of embodiment 36, wherein the solvent is isopropanol/water, toluene/heptanes and acetonitrile/water.
[00135] 40. The process of embodiment 39, wherein the solvent is toluene/heptanes and the solvent used is 0.5/3 to 1/2 parts v/w of the compound of formula 3 or 4.
[00136] 41. The process of embodiment 39, wherein the solvent is acetonitrile/water and the solvent used is 8/1 to 5/1 parts v/w of the compound of formula 3 or 4.
[00137] 42. The process of embodiment 39, wherein the solvent is isopropanol/water and the solvent used is 0.5/3 to 2/1 parts v/w of the compound of formula 3 or 4.
[00138] 43. The process of any one of embodiments 36 to 42, wherein the compound of formula 3 or 4 has a purity of 98 /0, as determined by HPLC.
[00139] Certain adaptations and modifications of the described embodiments can be made. Therefore, the above discussed embodiments are considered to be illustrative and not restrictive.
[00138] 43. The process of any one of embodiments 36 to 42, wherein the compound of formula 3 or 4 has a purity of 98 /0, as determined by HPLC.
[00139] Certain adaptations and modifications of the described embodiments can be made. Therefore, the above discussed embodiments are considered to be illustrative and not restrictive.
Claims (43)
1. A process for preparation of the compound of formula 4, the process comprising:
- nucleophillic addition reaction of the compound of formula 1 with a compound of formula Ar-M to form the compound of formula 2;
- dehydrating the compound of formula 2 to form the compound of formula 3 or 4;
- optionally, deprotecting the compound of formula 3; and - optionally, acylating the compound of formula 3 to form the compound of formula 4, wherein R is H or an alcohol protecting group;
R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group;
M is alkali metal, alkali earth metal or a transition metal of group 11 or 12;
Ar is an aryl or heteroaryl group and Ac is an acyl group.
- nucleophillic addition reaction of the compound of formula 1 with a compound of formula Ar-M to form the compound of formula 2;
- dehydrating the compound of formula 2 to form the compound of formula 3 or 4;
- optionally, deprotecting the compound of formula 3; and - optionally, acylating the compound of formula 3 to form the compound of formula 4, wherein R is H or an alcohol protecting group;
R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group;
M is alkali metal, alkali earth metal or a transition metal of group 11 or 12;
Ar is an aryl or heteroaryl group and Ac is an acyl group.
2. The process according to claim 1, wherein Ar is a heteroaryl group.
3. The process according to claim 1, wherein Ar is pyridinyl.
4. The process according to claim 1, wherein Ar is 3-substituted pyridinyl.
5. The process according to any one of claims 1 to 4, wherein R is an alcohol protecting group.
6. The process according to any one of claims 1 to 4, wherein R is an alcohol protecting group and the alcohol protecting group is acetyl.
7. The process according to any one of claims 1 to 4, wherein R is an alcohol protecting group and the alcohol protecting group is a silyl-based protecting group.
8. The process according to claim 7, wherein the silyl-based protecting group is tert-butyldimethylsilyl (TBDMS or TBS).
9. The process according to any one of claims 1 to 8, wherein M is alkali metal.
10. The process according to claim 9, wherein the alkali metal is Li.
11. The process according to any one of claims 1 to 10, wherein R1 is H.
12. The process according to any one of claims 1 to 10, wherein R1 together with the oxygen to which it is attached forms a leaving group.
13. The process according to any one of claims 1 to 10, wherein R1 together with the oxygen to which it is attached forms a leaving group and the leaving group is mesylate or tosylate.
14. The process according to any one of claims 1 to 13, wherein the step of dehydrating the compound of formula 2 is carried out in the presence of an acid.
15. The process according to claim 14, wherein the acid is hydrochloric acid (HCI) or p-toluene sulfonic acid (pTSA).
16. The process according to any one of claims 1 to 13, wherein the step of dehydrating the compound of formula 2 is carried out in the presence of a base.
17. The process according to claim 16, wherein the base is triethylamine (TEA).
18. The process according to any one of claims 1 to 17, wherein the step of deprotecting the compound of formula 3 is carried out in the presence of an acid.
19. The process according to any one of claims 1 to 17, wherein the step of deprotecting the compound of formula 3 is carried out in using a fluoride source.
20. The process according to any one of claims 1 to 19, wherein the step of acylating comprises acetylating the compound of formula 3.
21. The process according to any one of claims 1 to 20, wherein the process comprises forming the compound of formula 4a
22. The compound of formula 2, wherein Ar is an aryl group;
R is H or an alcohol protecting group; and R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group.
R is H or an alcohol protecting group; and R1 is H, an alcohol protecting group or R1 together with the oxygen to which it is attached forms a leaving group.
23. The compound of claim 22, wherein Ar is pyridinyl.
24. The compound of claim 23, wherein the compound of formula 2 is a compound of formula 2a
25. The compound of any one of claims 22 to 24, wherein R1 is H.
26. The compound of any one of claims 22 to 24, wherein R1 together with the oxygen to which it is attached forms a leaving group.
27. The compound of any one of claims 22 to 26, wherein R is acetyl.
28. The compound of any one of claims 22 to 26, wherein R is a silyl-based protecting group.
29. The compound of formula 3, wherein Ar is an aryl group; and R is a silyl-based protecting group.
30. The compound of claim 29, wherein Ar is pyridinyl.
31. The compound of claim 29 or 30, wherein the compound is the compound of formula 3a
32. The compound of any one of claims 29 to 31, wherein the silyl-based protecting group is tert-butyldimethylsilyl (TBDMS or TBS).
33. Abiraterone acetate having a purity of >=95%, >=96%, >=97%, >=98%, >=99%, >=99.5% or >=99.9%, as determined by HPLC.
34. The compound of formula 3 or 3a having a purity of >=95%, >=96%, >=97%, >=98%, >=99%, >=99.5% or >=99.9%, as determined by HPLC.
35. The compound of formula 2 or 2a having a purity of >=95%, >=96%, >=97%, >=98%, >=99%, >=99.5% or >=99.9%, as determined by HPLC.
36. A process for purification of the compound of formula 3 or 4, wherein R is H or an alcohol protecting group; Ar is an aryl or heteroaryl group and Ac is an acyl group;
the process comprising the step of recrstallizing the compound of formula 3 or 4 with a solvent selected from the group consisting of methanol, ethanol, isopropanol, isopropanol/water, toluene/heptanes and acetonitrile/water.
the process comprising the step of recrstallizing the compound of formula 3 or 4 with a solvent selected from the group consisting of methanol, ethanol, isopropanol, isopropanol/water, toluene/heptanes and acetonitrile/water.
37. The process of claim 36, wherein the solvent is methanol, ethanol or isopropanol.
38. The process of claim 37, wherein the solvent used is 3 to 10 parts v/w of the compound of formula 3 or 4.
39. The process of claim 36, wherein the solvent is isopropanol/water, toluene/heptanes and acetonitrile/water.
40. The process of claim 39, wherein the solvent is toluene/heptanes and the solvent used is 0.5/3 to 1/2 parts v/w of the compound of formula 3 or 4.
41. The process of claim 39, wherein the solvent is acetonitrile/water and the solvent used is 8/1 to 5/1 parts v/w of the compound of formula 3 or 4.
42. The process of claim 39, wherein the solvent is isopropanol/water and the solvent used is 0.5/3 to 2/1 parts v/w of the compound of formula 3 or 4.
43. The process of any one of claims 36 to 42, wherein the compound of formula 3 or 4 has a purity of >=98%, as determined by HPLC.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261637048P | 2012-04-23 | 2012-04-23 | |
| US61/637,048 | 2012-04-23 | ||
| US201261642253P | 2012-05-03 | 2012-05-03 | |
| US61/642,253 | 2012-05-03 | ||
| PCT/CA2013/050311 WO2013159225A1 (en) | 2012-04-23 | 2013-04-22 | Process for preparation of 17-substituted steroids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2871314A1 true CA2871314A1 (en) | 2013-10-31 |
Family
ID=49482082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2871314A Abandoned CA2871314A1 (en) | 2012-04-23 | 2013-04-22 | Process for preparation of 17-substituted steroids |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2841444A4 (en) |
| CA (1) | CA2871314A1 (en) |
| WO (1) | WO2013159225A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2877482A4 (en) * | 2012-07-25 | 2016-04-06 | Mapi Pharma Ltd | Process and intermediates for the preparation of abiraterone acetate |
| WO2015200837A1 (en) * | 2014-06-27 | 2015-12-30 | Fl Therapeutics Llc | Abiraterone derivatives and non-covalent complexes with albumin |
| EP3824908A1 (en) | 2015-04-10 | 2021-05-26 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
| CN105503992A (en) * | 2016-01-22 | 2016-04-20 | 江苏联环药业股份有限公司 | Preparation method of abiraterone acetate |
| CN107722101A (en) * | 2017-11-03 | 2018-02-23 | 郑州大学 | Steroidal pyridine derivatives and its preparation method and application |
| CA3131034A1 (en) | 2019-03-06 | 2020-09-10 | Matthew J. Sharp | Abiraterone prodrugs |
| JP2024506382A (en) | 2021-02-15 | 2024-02-13 | プロペラ セラピューティクス インコーポレイテッド | Abiraterone prodrug |
| CN117683073A (en) * | 2023-12-15 | 2024-03-12 | 江苏希迪制药有限公司 | Synthesis method of abiraterone acetate |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2938030A (en) * | 1956-10-03 | 1960-05-24 | Ciba Pharm Prod Inc | New steroids substituted by a heterocyclic nitrogen-containing ring in 17-position |
| WO1993020097A1 (en) * | 1992-03-31 | 1993-10-14 | British Technology Group Ltd. | 17-substituted steroids useful in cancer treatment |
| ES2127413T3 (en) * | 1993-09-30 | 1999-04-16 | Btg Int Ltd | SYNTHESIS OF STEROIDS 17- (3-PIRIDILO). |
| CN101768199B (en) * | 2009-12-24 | 2014-03-26 | 深圳万乐药业有限公司 | Polymorphs of abiraterone acetate and preparation method thereof |
| CN102321142A (en) * | 2011-09-29 | 2012-01-18 | 重庆医药工业研究院有限责任公司 | Abiraterone acetate crystal form and preparation method thereof |
| EP2607371A1 (en) * | 2011-12-23 | 2013-06-26 | Crystal Pharma, S.A.U. | Processes for the preparation of abiraterone and related compouds |
| EP2877482A4 (en) * | 2012-07-25 | 2016-04-06 | Mapi Pharma Ltd | Process and intermediates for the preparation of abiraterone acetate |
| CN102898495B (en) * | 2012-11-12 | 2014-11-26 | 浙江神洲药业有限公司 | Method for preparing abiraterone acetate |
-
2013
- 2013-04-22 EP EP13780667.5A patent/EP2841444A4/en not_active Withdrawn
- 2013-04-22 CA CA2871314A patent/CA2871314A1/en not_active Abandoned
- 2013-04-22 WO PCT/CA2013/050311 patent/WO2013159225A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2841444A4 (en) | 2015-11-04 |
| EP2841444A1 (en) | 2015-03-04 |
| WO2013159225A1 (en) | 2013-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2871314A1 (en) | Process for preparation of 17-substituted steroids | |
| ES2624667T3 (en) | Procedure for the preparation of estetrol | |
| JP3722835B2 (en) | Synthesis of 17- (3-pyridyl) steroids | |
| CA2851330C (en) | Process for preparing 17-substituted steroids | |
| EP0312867B1 (en) | Billiary acid derivatives, processes for the preparation thereof and phamaceutical compositions containing them | |
| CA2859897A1 (en) | Synthesis of abiraterone and related compounds | |
| US9663550B2 (en) | Method for preparing abiraterone acetate | |
| Májer et al. | New highly toxic bile acids derived from deoxycholic acid, chenodeoxycholic acid and lithocholic acid | |
| US10273263B2 (en) | Pro-drug forming compounds | |
| BR112013030833B1 (en) | process for the preparation of a compound of formula (i) and process for the preparation of estetrol | |
| AU775831B2 (en) | Process for preparing 17alpha-acetoxy-11beta-(4-N,N-(dimethylamino)phenyl)-21- methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates | |
| JP6904519B2 (en) | Manufacturing methods and intermediates for synthesizing intermediates for the antitumor drug niraparib | |
| CN110804082A (en) | A kind of cholic acid derivative and its preparation method and application | |
| WO2020155613A1 (en) | Preparation method for ecteinascidin compound and intermediate thereof | |
| CN102964414A (en) | Synthesis method of 17-position steroid carboxylic ester | |
| ES2581317T3 (en) | Preparation process of abiraterone or abiraterone acetate | |
| EP2917225A1 (en) | Process for making abiraterone-3-acetate | |
| EP2917226A1 (en) | Process for making the 17-triflate intermediate of abiraterone-3-acetate | |
| JPS6118559B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20190423 |